Investor Intelligence Business Intelligence Clients

Actionable Market Intel

Decoding the Balance of Power between Bulls and Bears AI, Algorithms, Insights and Answers for Investors

IBN Spotlight Company

Greenwave Technology Solutions Inc. (NASDAQ: GWAV)

Greenwave Technology Solutions Inc., through its wholly owned subsidiary Empire Services Inc., operates a network of 13 metal recycling facilities located across Virginia, North Carolina, and Ohio. These facilities specialize in the collection, classification, and processing of raw scrap metal, both ferrous and nonferrous. By efficiently managing and repurposing scrap metal, Greenwave plays a crucial role in the recycling industry, contributing to the sustainability and conservation of natural resources.

Profile

IBN Spotlight Company

WiSA Technologies Inc. (NASDAQ: WISA)

WiSA Technologies Inc. is a pioneering leader in immersive, wireless sound technology, providing cutting-edge audio solutions for intelligent devices and next-generation home entertainment systems. The company collaborates with top consumer electronics (CE) brands and manufacturers, including industry giants like Harman International (a division of Samsung), LG, Hisense, TCL, Bang & Olufsen, and Platin Audio. WiSA Technologies delivers exceptional wireless sound experiences for high-definition content, including movies, music, sports, gaming, and esports, thereby enhancing the overall consumer experience in home entertainment.

Profile

IBN Spotlight Company

Telomir Pharmaceuticals Inc. (NASDAQ: TELO)

Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on developing and commercializing Telomir-1, a groundbreaking small molecule designed to lengthen DNA’s protective telomere caps. Telomeres, the end caps of chromosomes, play a crucial role in protecting DNA from degradation, but they naturally shorten as humans and animals age, contributing to the onset of degenerative and age-related diseases. By targeting telomere lengthening, Telomir-1 has the potential to address these conditions and promote longevity, with applications for both humans and pets.

Profile

IBN Spotlight Company

NanoViricides Inc. (NYSE American: NNVC)

NanoViricides Inc. is a clinical stage global leader in the development of nanomedicine drugs against viruses.  Going beyond what antibodies and immunotherapeutics do, the company’s unique nanoviricide® platform technology is designed to specifically target and dismantle enveloped virus particles, offering a novel approach to treating a wide range of viral infections. NanoViricides' lead drug candidate, NV-387, is being developed for the treatment of respiratory viral infections, including RSV, COVID-19, Long COVID, and Influenza, with the company currently advancing NV-387 into Phase II human clinical trials. Another advanced candidate, NV-HHV-1, targets Shingles and represents a significant step forward in the treatment of viral diseases.

Profile

IBN Spotlight Company

TC BioPharm Holdings PLC (NASDAQ: TCBP)

TC BioPharm Holdings PLC is a clinical-stage biopharmaceutical company pioneering the development and commercialization of gamma-delta T cell therapies for the treatment of cancer, with a particular focus on acute myeloid leukemia (AML). Gamma-delta T cells are unique immune cells that possess characteristics of both the innate and adaptive immune systems, allowing them to distinguish between healthy and diseased tissues. This dual capability makes them a powerful tool in the fight against cancer, and TC BioPharm is at the forefront of harnessing this potential to develop innovative therapeutics.

Profile

IBN Spotlight Company

Gaxos.ai Inc. (NASDAQ: GXAI)

Gaxos.ai Inc. is revolutionizing the human-AI relationship, pushing the boundaries of artificial intelligence to offer solutions that resonate on a human level. The company's mission extends beyond application development; it aims to integrate AI into various aspects of human existence, transforming how people interact with technology. With a strong commitment to enhancing quality of life, Gaxos.ai focuses on creating AI-driven solutions that address health, longevity, and entertainment, making advanced technology accessible and beneficial to all.

Profile

IBN Spotlight Company

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics aimed at treating and preventing human diseases and alleviating suffering. The company's development portfolio is primarily focused on central nervous system (CNS) disorders, with its lead product candidate, TNX-102 SL, showing significant promise for the management of fibromyalgia. With two successful Phase 3 studies completed, Tonix is preparing to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, which has also been granted Fast Track designation. In addition to fibromyalgia, TNX-102 SL is being developed to treat acute stress reactions, further broadening its therapeutic potential.

Profile

IBN Spotlight Company

Silo Pharma Inc. (NASDAQ: SILO)

Silo Pharma Inc. is a cutting-edge biopharmaceutical company focused on developing novel therapeutics to address underserved medical conditions, particularly in the fields of stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company is at the forefront of integrating conventional drug therapies with innovative psychedelic treatments, utilizing advanced formulations and drug delivery systems to enhance efficacy and patient outcomes. Through strategic collaborations with universities and independent laboratories, Silo Pharma is pioneering a new era in biopharmaceutical research and development.

Profile

IBN Spotlight Company

Oragenics Inc. (NYSE American: OGEN)

Oragenics Inc. is a development-stage biotechnology company pioneering innovative solutions in pharmaceutical medications, with a focus on nasal delivery systems. The company addresses critical unmet medical needs in neurology and infectious diseases, with research centered on developing drug candidates for mild traumatic brain injuries, such as concussions, and rare neurodegenerative disorders like Niemann-Pick Disease Type C. These areas represent significant challenges within the medical community due to limited treatment options making Oragenics' mission especially impactful.

Profile

During the last 18+ years IBN has represented over 500 public and private companies across multiple industries and sectors. Corporations large and small have chosen IBN’s platform services for unparalleled visibility and recognition utilizing our proprietary CORE Relations SolutionsBrand Awareness, Corporate Communications and Social Media Solutions.

IBN’s platform solutions can build or reposition a brand, help launch a new product or service, assist in an uplisting, or pave the way for an IPO, a merger or an acquisition.

IBN client partners from private start-ups to large public companies turn to us for integrated support and tech savvy communications systems. Our proprietary techniques and platform solutions cut through clutter to effectively reach the largest target markets and most desirable demographics possible. IBN is committed to delivering each client partner results that exceed expectations. Please review our Covered Companies Index (CCI).

 

Press Release Distribution with InvestorWire

InvestorWire represents an expansive network of wire services to ensure the best distribution of your news to ever-expanding audiences. Our network of distribution points enables clients to rise above the commotion and reach all target markets, industries and demographics.

Choose a press release coverage package that fits your need.

* Meets news distribution requirements for dual-listed entities.

InvestorBrandNetwork ClientWriter On ComputerAccount Executive on Phone
AudioPressRelease ProductionWoman Listening to AudioPressReleaseCannabis Focused Distribution - Hemp CBD OilMan producing AudioPressRelease
Enhance your press release coverage with InvestorWire’s specialty solutions.

Let's get started.

Interested in a live, online demonstration? Schedule a date and time that works for you.

Schedule a LIVE Demo

Questions about IBN and our solutions? Call or send us an email.

(310) 299-1717

You’re already more familiar with brand awareness than you might think. What’s your favorite brand of soft drink, athletic shoe, car, shampoo, streaming content provider? Chances are, you first tried those brands because of their awareness strategies. Whether it was word of mouth or a TV commercial, Facebook post, billboard or coupon, that awareness peaked interest, triggered a purchase reaction, and ideally built customer loyalty.

More About Brand Awareness

5,000+ key syndication outlets across the country. IBN’s extensive system of strategic distribution points maximizes your exposure to an audience of millions, including journalists, investors, day traders, fund managers and a multitude of other interested individuals. Now your press releases, earnings statements, branded articles, shareholder updates, corporate achievements can reach a vast and diverse nationwide audience.

More About InvestorWire

Make sure your message resonates. IBN integrates social media with traditional distribution channels to make sure your message resonates long after initial publication. This innovative model ensures that your news not only crosses the wire, but keeps reverberating via social conversation on Twitter, Facebook, LinkedIn and other social networks.

More About Social MediaIBN Social Media NetworkSocial Media Statistics & FAQs

A unique format with a traditionally different sensory input – hearing.As conferences and events continue to suffer cancellations and greatly reduced attendance, many businesses are wondering how to network with large investor audiences in the new normal. At the same time podcasts have seen a jump in popularity.

More About IBN Podcast Solutions